Please Scroll Down to See Forums Below 
.jpg "Research Chemical Sciences")
.png "Research Chemical Sciences")
MassiveG300
New member
Schering has just gotten approval.
Testosterone Undecanoate has been around for some time in UG/BM BB'ing circles and described as "nothing special" for traditional cycling patterns and gains.
It should however work quite well in those that are needle phobic and using it for replacement.
Interesting to note-it won't be released in the US.
It may have some application in those that are traveling as 1g will give you about normal test for 14 weeks, so 2g should give you about double normal levels.
The Undecanoate ester has been available for some time on the Underground Black Market-but so far hasn't really been reported as anything special due to the availability of the regular esters and the mormal cyclic patterns in which they are used.
"Nebido®
Testosterone preparation for intramuscular injection in male hypogonadism
Composition: Each ampoule contains 1000 mg testosterone undecanoate in a 4-ml solution for injection (250 mg testosterone undecanoate/ml).
Nebido® is the first 3-monthly injectable testosterone preparation for the treatment of male hypogonadism. Nebido® offers long-lasting testosterone levels in the eugonadal range. It reliably and significantly improves all symptoms associated with hypogonadism.
With Nebido® testosterone levels remain constantly - for up to 14 weeks - in the eugonadal range, avoiding unphysiological peaks and troughs. Patients value the consistent, reliable efficacy and the long duration of effect, which mean they are not dependent on taking frequent medication. Consequently, Nebido® is believed to become the standard preparation for long-term treatment.
Nebido® is injected deeply into the gluteal muscle. Following administration, testosterone undecanoate is gradually released from the depot and is cleaved by serum esterases into testosterone and undecanoic acid. An increase of serum testosterone concentrations above basal values can already be measured the very next day after injection.
Nebido® will be introduced in Europe, starting in Finland and Germany, autumn 2004. Other European countries will follow in 2005. Launches in Latin American and Asian will start 2005.
Testosterone Undecanoate has been around for some time in UG/BM BB'ing circles and described as "nothing special" for traditional cycling patterns and gains.
It should however work quite well in those that are needle phobic and using it for replacement.
Interesting to note-it won't be released in the US.
It may have some application in those that are traveling as 1g will give you about normal test for 14 weeks, so 2g should give you about double normal levels.
The Undecanoate ester has been available for some time on the Underground Black Market-but so far hasn't really been reported as anything special due to the availability of the regular esters and the mormal cyclic patterns in which they are used.
"Nebido®
Testosterone preparation for intramuscular injection in male hypogonadism
Composition: Each ampoule contains 1000 mg testosterone undecanoate in a 4-ml solution for injection (250 mg testosterone undecanoate/ml).
Nebido® is the first 3-monthly injectable testosterone preparation for the treatment of male hypogonadism. Nebido® offers long-lasting testosterone levels in the eugonadal range. It reliably and significantly improves all symptoms associated with hypogonadism.
With Nebido® testosterone levels remain constantly - for up to 14 weeks - in the eugonadal range, avoiding unphysiological peaks and troughs. Patients value the consistent, reliable efficacy and the long duration of effect, which mean they are not dependent on taking frequent medication. Consequently, Nebido® is believed to become the standard preparation for long-term treatment.
Nebido® is injected deeply into the gluteal muscle. Following administration, testosterone undecanoate is gradually released from the depot and is cleaved by serum esterases into testosterone and undecanoic acid. An increase of serum testosterone concentrations above basal values can already be measured the very next day after injection.
Nebido® will be introduced in Europe, starting in Finland and Germany, autumn 2004. Other European countries will follow in 2005. Launches in Latin American and Asian will start 2005.
